Shalby consolidated PAT up 8% YoY to ₹7.9 Cr as Medtech losses widen further
PAT +8.35% YoY · revenue +9.72% · margins compressing
₹313.17 Cr
+9.72% YoY
₹7.89 Cr
+8.35% YoY
2.48%
0pp YoY
₹0.73
Shalby's consolidated revenue came in at ₹313.17 Cr (+9.7% YoY, -5.5% QoQ) and consolidated PAT at ₹7.89 Cr (+8.4% YoY, -24.9% QoQ) for Q2 FY27. No quarter-specific street estimate for Q2 FY27 could be located (trackers show only full-year FY27 consensus — EPS ₹4.20, +30% — with a near-unanimous Buy rating), so vs-street is unknown rather than graded.
Q2 FY-2027 vs prior quarters
NPM was essentially flat YoY at 2.52% (vs 2.51%) but down sequentially from 3.10% in Q1 FY27; OPM came in at 13.22%, down from 14.58% a year ago though up from Q1's 12.56%. The Healthcare Services segment, the core of the business, grew PBT 9.8% YoY to ₹28.11 Cr on 12.1% revenue growth to ₹283.21 Cr — consistent with management's push toward the 20% hospital EBITDA margin target it set out for FY27 in the August 2026 concall, though no EBITDA breakout is disclosed to confirm the exact trajectory. Working against this, the Manufacturing & Trading of Implants (Medtech) segment's loss widened 78% YoY to ₹11.64 Cr on an 8.8% revenue decline to ₹29.97 Cr — the opposite of management's guidance that regulatory changes would bring Medtech to double-digit EBITDA margins within 6-9 months. The segment's deterioration coincides with Shalby Medtech CEO Deepak Anand's resignation on August 18, 2026, with no replacement named in this filing.
The stock went into the print at ₹122.13, down 8.6% over the past month of trading.
Hospital EBITDA margin targeting upward to 20% for FY27. MedTech targeting double-digit EBITDA margins post-regulatory changes (6-9 months). ROCE expansion to 11-13% industry standard within 1-2 years via capex ROI and minimal further capex planned.
— This quarter: missed
No management press release accompanies this result, so there is no company framing to reconcile against the numbers. Standalone PAT of ₹23.50 Cr (EPS ₹2.19) is well above consolidated PAT of ₹7.89 Cr (EPS ₹0.73); the gap is entirely subsidiary-level losses, chiefly Medtech, consolidating down group profit. Both statements carry no exceptional items this quarter or a year ago, so YoY growth is on a clean base. Separately, the board approved appointing Shanay Vikram Shah and Tushar Shah as Whole-Time/Executive directors, subject to a shareholder postal ballot due December 5, 2026 — a governance move unconnected to this quarter's operating print.
W1
Medtech segment EBITDA margin trajectory — management guided double-digit margins within 6-9 months of regulatory changes (Aug 2026 concall); segment loss was ₹11.64 Cr this quarter, widened from ₹6.52 Cr YoY
W2
Hospital EBITDA margin progress toward management's 20% FY27 target — Healthcare segment PBT margin was ~9.9% this quarter
W3
Jabalpur hospital fire disruption (registration suspended Oct 14, 2026; full operations resumed Oct 28, 2026) falls in Q3 FY27 — watch for revenue/margin impact in the next print
Source is in ₹ Million, converted to Crore (÷10). No exceptional items in current or year-ago quarter (both periods). Consolidated 'Profit for the period' (₹7.886 Cr, before NCI split) is used as netProfit, consistent with DB convention — this exact figure reconciles with the prior-quarter (₹10.496 Cr) and year-ago (₹7.278 Cr) DB values pulled from this same statement's columns. Tax figure derived as current tax + adjustment for earlier years + deferred tax (MAT credit nil this quarter).
Informational and educational content only. Not investment advice.